Marqibo is a prescription medication approved by the U.S. food and drug administration (FDA) used to treat adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Marqibo is indicated in cases where Ph- ALL has relapsed two or more times after trying two or more different therapies. Marqibo is also known by its drug name, vincristine sulfate liposome.
Marqibo is an anticancer drug used in chemotherapy. Marqibo is a member of a class of drugs called plant alkaloids. Marqibo is believed to work by interfering with the structure of cancer cells.
How do I take it?
Marqibo is administered as an intravenous infusion once every seven days.
The FDA-approved label for Marqibo lists common side effects including fatigue, fever, insomnia, loss of appetite, nausea, diarrhea, constipation, peripheral neuropathy (numbness or tingling in the extremities), and low blood cell counts.
Rare but serious side effects listed for Marqibo include nerve damage, liver damage, bowel obstruction, and fetal harm in pregnant women. Marqibo may also cause tumor lysis syndrome – a potentially fatal metabolic condition caused when many cancer cells die at the same time.
For more details about this treatment, visit:
Marqibo — Spectrum
ALL: Relapsed and Refractory — Leukemia & Lymphoma Society